BioSyent RX.V · CAD

Its shares trade on TSX Venture under the ticker RX.V. It has been listed since 22 May 1981. In the fiscal year to 31 December 2025, it reported revenue of C$43.1m and net income of C$9.0m. At that date it held total assets of C$49.4m and shareholders' equity of C$41.5m.

BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. The company is headquartered in Etobicoke, Ontario. The Company, through its subsidiary, BioSyent Pharma Inc., acquires or in-licenses and develops pharmaceutical products for sale in Canada and certain international markets. The company has four business units: the Community and Women's Health Unit, which commercializes pharmaceutical products focused on improving family and women's health; the Hospital Business Unit, which sells pharmaceutical products to hospitals and hospital specialists; the International Pharmaceutical Unit, and the Legacy Business. Its products include FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Aguettant System and Cysview. FeraMAX 150 is an oral hematinic indicated for the prevention and treatment of iron deficiency anemia. Cathejell is indicated for surface anesthesia and lubrication for various procedures. RepaGyn helps relieve dryness and promotes healing of the vaginal mucosa. The company also manufactures and markets Protect-It, a non-toxic product.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Rene GoehrumChairman of the Board, President and Chief Executive Officer, since 1996C$761,523
• Mr. Robert MarchChief Financial Officer, Vice President - FinanceC$356,750
• Ms. Marnie MccormickVice President and General ManagerC$250,035
• Mr. Kevin WilsonVice President - SalesC$255,093
• Mr. Joost Van Der MarkVice President- Corporate DevelopmentC$348,580
• Ms. Neelu AtwalDirector - Human Resources
• Mr. Navid AshrafiDirector- Medical and Regulatory AffairsC$264,585
• Mr. Ramesh MoothanDirector - International Business Unit
• Mr. Sharan RaghubirDirector - Specialty Sales, since 2022C$195,463
• Mr. Peter LockhardLead Independent DirectorC$45,000
• Mr. Joseph ArcuriIndependent Director, since 2003C$45,686
• Ms. Sara ElfordIndependent DirectorC$41,500

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.